Vaccine Strategies for the Treatment of Lymphoma: Preclinical Progress and Clinical Trial Update
Thomas U. Marron(Icahn School of Medicine at Mount Sinai), Joshua Brody(New York University), Peter Martin(Northwestern University), Lukas Ronner(Hospital of the University of Pennsylvania), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center)
Cited by 11
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
|Immunity|2016|1.2k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k